基于网络药理学和分子对接探讨蛇床子治疗乳腺癌的作用机制

doi:10.3976/j.issn.1002-4026.2022.06.007

Abstract

Abstract:

The study aimed to investigate the potential therapy targets and pharmacological mechanism of Cnidii Fructus for the treatment of breast cancer using network pharmacology and molecular docking. The active components of Cnidii Fructus and the potential targets of active components were obtained via the traditional Chinese medicine systems pharmacology database and analysis platform, and the gene conversions were obtained using the UniProt database. The targets of breast cancer were retrieved from GeneCards and OMIM database. The Venn online software was used to obtain the common targets of drug and disease, and then the drug-compound-target-disease network diagram was constructed using the Cytoscape 3.7.2 software. The STRING database was employed to draw the protein-protein interaction network. Further, the DAVID database was used to perform gene ontology function and Kyoto encyclopedia of genes and genomes pathway enrichment analysis on the effective targets, and the AutoDock software was used to verify the molecular docking of active components and core targets. The results revealed that 17 active components of the Cnidii Fructus regulated 19 targets and 56 pathways to treat breast cancer. The four key compounds were beta-sitosterol, (E)-2,3-bis(2-keto-7-methoxy-chromen-8-yl)acrolein, stigmasterol, and osthol, which generally mediate pathways in cancer, proteoglycans in cancer, focal adhesion, PI3K-Akt, and other signaling pathways. These pathways are mediated via HSP90AA1, JUN, PRKACA, KDR, and other key targets to exert the anti-breast cancer effects. The study preliminarily reveals the molecular mechanism of Cnidii Fructus against breast cancer and provides a theoretical basis for the clinical application of Cnidii Fructus and its related research on breast cancer.

Key words: network pharmacology, molecular docking, Cnidii Fructus, breast cancer, mechanism of action

CLC Number:

R285

KE Chang-hu, PAN Chang-jiang, YAN Hui, LIU Jia-ling, CHEN Miao, LI Zhi-hao. Using network pharmacology and molecular docking to determine the mechanism of Cnidii Fructus in the treatment of breast cancer[J].Shandong Science, 2022, 35(6): 50-57.

Figures/Tables 4

Table 1

Fig.1

Fig.2

Table 2

References 37

[1]	International Agency for Research on Cancer. Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020[EB/OL].[2021-05-12]. https://www.iarc.who.int/fr/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/.
[2]	章必成, 朱诗聪, 宋启斌. 乳腺癌免疫治疗的最新进展[J]. 医药导报, 2019, 38(8): 1013-1016. DOI:10.3870/j.issn.1004-0781.2019.08.007. doi: 10.3870/j.issn.1004-0781.2019.08.007
[3]	BARZAMAN K, KARAMI J, ZAREI Z, et al. Breast cancer: Biology, biomarkers, and treatments[J]. International Immunopharmacology, 2020, 84: 106535. DOI:10.1016/j.intimp.2020.106535. doi: 10.1016/j.intimp.2020.106535
[4]	国家药典委员会. 中华人民共和国药典2020年版一部[M]. 北京: 中国医药科技出版社, 2020:328.
[5]	宋更申, 徐艳梅, 周丽, 等. GC-MS法同时测定蛇床子中7种香豆素类活性成分[J]. 药学学报, 2016, 51(4): 626-630. DOI:10.16438/j.0513-4870.2015-0649. doi: 10.16438/j.0513-4870.2015-0649
[6]	郑丹丹, 阮静雅, 张颖, 等. 蛇床子中黄酮类化学成分的分离与结构鉴定[J]. 中国药物化学杂志, 2020, 30(9): 542-548. DOI:10.14142/j.cnki.cn21-1313/r.2020.09.004. doi: 10.14142/j.cnki.cn21-1313/r.2020.09.004
[7]	朱缨, 谈如蓝, 吴芝园, 等. 山东产蛇床子挥发油化学成分研究[J]. 中国药业, 2016, 25(11): 31-33.
[8]	LI J J, CHEN W L, WANG J Y, et al. Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model[J]. Acta Pharmacologica Sinica, 2017, 38(10): 1369-1380. DOI:10.1038/aps.2017.13. doi: 10.1038/aps.2017.13
[9]	张帅, 刘胜. 顾氏外科乳腺癌治验[J]. 吉林中医药, 2017, 37(3): 241-244. DOI:10.13463/j.cnki.jlzyy.2017.03.008. doi: 10.13463/j.cnki.jlzyy.2017.03.008
[10]	史有阳, 杨瑞, 孙霃平. 刘胜教授基于五脏相关理论治疗晚期乳腺癌经验[J]. 西部中医药, 2021, 34(5): 39-41. DOI:10.12174/j.issn.2096-9600.2021.05.10. doi: 10.12174/j.issn.2096-9600.2021.05.10
[11]	MEI J, WANG T J, ZHAO S J, et al. Osthole inhibits breast cancer progression through upregulating tumor suppressor GNG7[J]. Journal of Oncology, 2021, 2021: 6610511. DOI:10.1155/2021/6610511. doi: 10.1155/2021/6610511
[12]	DAI X, YIN C, ZHANG Y, et al. Osthole inhibits triple negative breast cancer cells by suppressing STAT3[J]. Journal of Experimental & Clinical Cancer Research, 2018, 37(1): 322. DOI:10.1186/s13046-018-0992-z. doi: 10.1186/s13046-018-0992-z
[13]	WU C Y, SUN Z P, GUO B F, et al. Osthole inhibits bone metastasis of breast cancer[J]. Oncotarget, 2017, 8(35): 58480-58493. DOI:10.18632/oncotarget.17024. doi: 10.18632/oncotarget.17024 pmid: 28938572
[14]	董培良, 李慧, 韩华. 中药网络药理学的应用与思考[J]. 中国实验方剂学杂志, 2020, 26(17): 204-211. DOI:10.13422/j.cnki.syfjx.20201740. doi: 10.13422/j.cnki.syfjx.20201740
[15]	解静, 高杉, 李琳, 等. 网络药理学在中药领域中的研究进展与应用策略[J]. 中草药, 2019, 50(10): 2257-2265.
[16]	JIAO X Y, JIN X, MA Y Y, et al. A comprehensive application: Molecular docking and network pharmacology for the prediction of bioactive constituents and elucidation of mechanisms of action in component-based Chinese medicine[J]. Computational Biology and Chemistry, 2021, 90: 107402. DOI:10.1016/j.compbiolchem.2020.107402. doi: 10.1016/j.compbiolchem.2020.107402
[17]	LIU H, WANG J N, ZHOU W, et al. Systems approaches and polypharmacology for drug discovery from herbal medicines: An example using licorice[J]. Journal of Ethnopharmacology, 2013, 146(3): 773-793. DOI:10.1016/j.jep.2013.02.004. doi: 10.1016/j.jep.2013.02.004 pmid: 23415946
[18]	AUNGST B J. Optimizing oral bioavailability in drug discovery: An overview of design and testing strategies and formulation options[J]. Journal of Pharmaceutical Sciences, 2017, 106(4): 921-929. DOI:10.1016/j.xphs.2016.12.002. doi: S0022-3549(16)41891-5 pmid: 27986598
[19]	郭帅. 蛇床子素对人乳腺癌MDA-MB-231细胞系增殖和凋亡的影响[D]. 锦州: 锦州医科大学, 2018.
[20]	关灵, 郑锐年, 吴少敏, 等. 蛇床子素体外抗乳腺癌活性研究[J]. 中医临床研究, 2018, 10(18): 118-123.
[21]	HSIN K Y, GHOSH S, KITANO H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology[J]. PLoS One, 2013, 8(12): e83922. DOI:10.1371/journal.pone.0083922. doi: 10.1371/journal.pone.0083922
[22]	程海波, 吴勉华. 周仲瑛教授“癌毒”学术思想探析[J]. 中华中医药杂志, 2010, 25(6): 866-869.
[23]	程旭锋, 张新峰, 刘琦, 等. 蛇床子-补骨脂配伍引经药对乳腺癌骨转移裸鼠CXCL12-CXCR4轴的影响[J]. 中国实验方剂学杂志, 2016, 22(16): 91-96. DOI:10.13422/j.cnki.syfjx.2016160091. doi: 10.13422/j.cnki.syfjx.2016160091
[24]	叶依依, 刘胜, 郭宝凤, 等. 蛇床子素配伍补骨脂素对人乳腺癌高骨转移细胞增殖及侵袭的影响[J]. 中华中医药学刊, 2013, 31(1): 36-40. DOI:10.13193/j.archtcm.2013.01.40.yeyy.040. doi: 10.13193/j.archtcm.2013.01.40.yeyy.040
[25]	张小慧, 韩向晖, 刘胜, 等. 温肾壮骨方对乳腺癌骨转移Tac1/NK1R通路蛋白的影响[J]. 中成药, 2014, 36(8): 1569-1573. DOI:10.3969/j.issn.1001-1528.2014.08.01. doi: 10.3969/j.issn.1001-1528.2014.08.01
[26]	张虎, 朱蕾. 蛇床子素通过p53信号通路诱导人乳腺癌细胞株MCF-7凋亡[J]. 中国现代应用药学, 2016, 33(5): 547-551. DOI:10.13748/j.cnki.issn1007-7693.2016.05.007. doi: 10.13748/j.cnki.issn1007-7693.2016.05.007
[27]	王倩, 郑海雅, 周颖, 等. 蛇床子素联合肿瘤坏死因子诱导凋亡配体对乳腺癌干细胞的杀伤效应[J]. 中国现代应用药学, 2017, 34(2): 225-231. DOI:10.13748/j.cnki.issn1007-7693.2017.02.016. doi: 10.13748/j.cnki.issn1007-7693.2017.02.016
[28]	陶仕英, 牛建昭, 王继峰, 等. β-谷甾醇对T47D细胞增殖和细胞周期的影响及作用机制探讨[J]. 世界科学技术-中医药现代化, 2015, 17(2): 362-366. DOI:10.11842/wst.2015.02.012. doi: 10.11842/wst.2015.02.012
[29]	GAUTAM M, THAPA R K, GUPTA B, et al. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid Phyto-liposomes for synergistic chemotherapy[J]. Expert Opinion on Drug Delivery, 2020, 17(3): 423-434. DOI:10.1080/17425247.2020.1727442. doi: 10.1080/17425247.2020.1727442
[30]	YANG D P, GU T W, WANG T, et al. Effects of osthole on migration and invasion in breast cancer cells[J]. Bioscience, Biotechnology, and Biochemistry, 2010, 74(7): 1430-1434. DOI:10.1271/bbb.100110. doi: 10.1271/bbb.100110
[31]	PARK W, PARK S, SONG G, et al. Inhibitory effects of osthole on human breast cancer cell progression via induction of cell cycle arrest, mitochondrial dysfunction, and ER stress[J]. Nutrients, 2019, 11(11): 2777. DOI:10.3390/nu11112777. doi: 10.3390/nu11112777
[32]	LIU H Z, ZHANG Z H, HUANG Y, et al. Plasma HSP90AA1 predicts the risk of breast cancer onset and distant metastasis[J]. Frontiers in Cell and Developmental Biology, 2021, 9: 639596. DOI:10.3389/fcell.2021.639596. doi: 10.3389/fcell.2021.639596
[33]	VLEUGEL M M, GREIJER A E, BOS R, et al. C-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer[J]. Human Pathology, 2006, 37(6): 668-674. DOI:10.1016/j.humpath.2006.01.022. doi: 10.1016/j.humpath.2006.01.022 pmid: 16733206
[34]	张岩. c-Jun与乳腺癌侵袭转移相关性的实验研究[D]. 重庆: 第三军医大学, 2007.
[35]	YANG F, XIE H Y, YANG L F, et al. Stabilization of MORC2 by estrogen and antiestrogens through GPER1-PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells[J]. Autophagy, 2020, 16(6): 1061-1076. DOI:10.1080/15548627.2019.1659609. doi: 10.1080/15548627.2019.1659609
[36]	张喆, 贾立周, 唐奇, 等. TROP2和VEGFR2在三阴性乳腺癌中的表达及与临床病理因素的相关性研究[J]. 南京医科大学学报(自然科学版), 2019, 39(10): 1453-1458.
[37]	李慧, 李春晓, 南鹏, 等. PI3K/AKT信号通路与HER2阳性乳腺癌患者总生存时间的相关性及验证分析[J]. 解放军医学杂志, 2018, 43(3): 217-223. DOI:10.11855/j.issn.0577-7402.2018.03.07. doi: 10.11855/j.issn.0577-7402.2018.03.07

编号	Mol ID	活性成分	中文名	OB/%	DL
1	MOL000449	Stigmasterol	豆甾醇	43.83	0.76
2	MOL001771	Poriferast-5-en-3beta-ol	穿贝海绵甾醇	36.91	0.75
3	MOL000358	Beta-sitosterol	β-谷甾醇	36.91	0.75
4	MOL001510	24-epicampesterol	22,23-二氢菜子甾醇	37.58	0.71
5	MOL003605	(E)-2,3-bis(2-keto-7-methoxy-chromen-8-yl)acrolein	—	56.38	0.71
6	MOL003591	Ar-curcumene	芳-姜黄烯	52.34	0.65
7	MOL003607	Cniforin B	—	36.70	0.60
8	MOL003606	Cniforin A	O-乙酰异蛇床素	55.89	0.47
9	MOL003624	O-Isovalerylcolum bianetin	邻-异戊酰基二氢山芹醇	64.03	0.36
10	MOL003604	Cnidimol F	—	54.43	0.28
11	MOL002881	Diosmetin	香叶木素	31.14	0.27
12	MOL003600	Cnidimol B	—	68.66	0.26
13	MOL003608	O-Acetylcolumbianetin	O-乙酰二氢欧山芹酯	60.04	0.26
14	MOL003617	Isogosferol	异栓翅芹醇	30.07	0.25
15	MOL003626	Ostruthin	欧芹素	30.65	0.23
16	MOL001941	Ammidin	欧前胡素	34.55	0.22
17	MOL003588	Prangenidin	别欧前胡素	36.31	0.22
18	MOL003584	Xanthoxylin N	美花椒内酯	35.51	0.21
19	MOL002883	Ethyl oleate (NF)	油酸乙酯	32.40	0.19
20	MOL000614	Osthol	蛇床子素	38.75	0.13

靶点	PDB ID	结合能/(kJ·mol^-1)
靶点	PDB ID	A	B	C	D
HSP90AA1	5NJX	-25.15	-21.67	-25.56	-21.13
JUN	1-jun	-18.95	-16.78	-19.83	-15.86
PRKACA	4021	-27.15	-28.45	-28.74	-21.09
KDR	2P2I	-28.37	-20.88	-28.58	-21.76

Using network pharmacology and molecular docking to determine the mechanism of Cnidii Fructus in the treatment of breast cancer

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 37

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIU Shuang, DONG Hongjing, CHEN Panpan, WANG Xiao. Research progress on the mechanisms by which natural phenolic compounds alleviate hyperuricemia [J]. Shandong Science, 2024, 37(2): 12-19.
[2]	LUO Yaqin, HUANG Wei. Progress in the research on the mechanism of action of Scutellaria baicalensis and its active ingredients in treating ulcerative colitis [J]. Shandong Science, 2024, 37(2): 20-28.
[3]	LIU Kechun, WANG Yongcheng, ZANG Xiaohan, XIA Qing, ZHANG Yun, ZHANG Shanshan, SUN Chen. Advancements in network pharmacology and zebrafish modeling for studying traditional Chinese medicine’s effective substances and mechanisms of action [J]. Shandong Science, 2024, 37(2): 29-35.
[4]	FU Zhaoju, CHENG Guo, LIN Dengmei, LI Jun, ZHANG Nannan. Experimental study and network pharmacological analysis of the anti-inflammatory action mechanism of Mahonia bealei (Fort.) Carr. [J]. Shandong Science, 2024, 37(1): 24-31.
[5]	CHEN Chun, QI Daqing, PAN Jingwen. Clinical significance of stromal cell score in gastric cancer and intervention with Weifuchun capsules [J]. Shandong Science, 2023, 36(6): 38-47.
[6]	MU Nana, LIAO Binbin, LI Zhen, LI Jipin, LI Yihua, WANG Ying, CHEN Xubing. Investigating the mechanism of action of Elephantopus scaber L. in the treatment of ulcerative colitis based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(6): 48-55.
[7]	WANG Yifan, ZHANG Zhe, TIAN Caijun. Mechanism of Sanhuang Xiexin decoction in treatment of Alzheimer's disease based on network pharmacology and molecular docking method [J]. Shandong Science, 2023, 36(5): 19-26.
[8]	FU Mengya, AO Huihao, BU Chao, PENG Tangyi, WU Deling, HAN Yanquan, HONG Yan. Forecast analysis of the quality markers of Zingiberis Rhizoma based on fingerprints and network pharmacology [J]. Shandong Science, 2023, 36(4): 35-41.
[9]	YIN Zhipeng, GAO Yunyun, LIU Wenwen, GUO Pengbo, ZHAO Yinghui. Exploring the mechanism of Xiangsha Liujunzi Decoction in treating Helicobacter pylori-associated gastritis based on network pharmacology and molecular docking technology [J]. Shandong Science, 2023, 36(4): 52-60.
[10]	SUN Tiefeng, DONG Limin, JIAO Ziqi, WANG Ping. Exploration of the dosing pattern and anti-respiratory syncytial virus mechanism of traditional Chinese medicine based on data mining and network pharmacology [J]. Shandong Science, 2023, 36(3): 1-9.
[11]	ZHU Jie, WANG Zheng, LIANG Yanni. The mechanism of Xiaoqinglong Decoction in treatment of COVID-19 based on network pharmacology [J]. Shandong Science, 2023, 36(3): 10-17.
[12]	DONG Pengjun, CAI Bin. Action mechanism of the herb pair Aurantii Fructus Immaturus-Magnoliae Officinalis Cortex in the treatment of slow transit constipation based on network pharmacology and metabolomics [J]. Shandong Science, 2023, 36(3): 18-26.
[13]	ZHAO Xin, HUANG Biyun, WU Dan, ZHANG Mei. The mechanism of Guishaozhenxian Tablet in the treatment of temporal lobe epilepsy based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(3): 27-37.
[14]	WANG Yifan, ZHANG Yanyan, TIAN Caijun. Network pharmacology to explore the mechanism of Wangbi formula in the treatment of rheumatoid arthritis [J]. Shandong Science, 2023, 36(3): 38-45.
[15]	LIU Wenwen, GAO Yunyun, YIN Zhipeng, LÜ Gang, WANG Yu, ZHAO Yinghui. Network pharmacology and molecular docking analysis of the mechanism of Huanglian Wendan Decoction in the treatment of Helicobacter pylori associated gastritis [J]. Shandong Science, 2023, 36(2): 23-32.